We are pleased to announce that on 24th June 2026, China Merchants Securities International (“CMSI”), acting as the Joint Sponsor, Overall Coordinator, Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager of Shaanxi Micot Pharmaceutical Technology Co., Ltd. (“Micot” or the “Company”, stock code: 2335.HK), successfully assisted the Company to commence trading of its shares on the Main Board of The Stock Exchange of Hong Kong Limited (“HKEx”).
Micot globally offered 58,054,400 shares at an issue price of HK$18.20 per share, with total proceeds of approximately HK$1.057 billion. The offering attracted a total of three cornerstone investors, including government entities and strategic partners, with cornerstone subscriptions accounting for 42.51% of the base offering size. During the offering stage, the Company's Hong Kong public offering was oversubscribed by 1,181 times, and the international placing was also oversubscribed, attracting participation from multiple professional institutions, reflecting the capital market's recognition of the Company’s value.
About Micot
Founded in 2007, Micot is a biotechnology company specializing in the discovery, development and commercialization of bi-/multi-specific peptide drugs for the treatment of metabolic diseases as well as cardiovascular and cerebrovascular diseases. Leveraging over a decade of experience in peptide drug R&D, the Company has self-developed a broad pipeline comprising one Core Product and six product candidates, targeting multiple therapeutic areas with significant unmet clinical needs, particularly in metabolic (kidney-related) and cardiovascular diseases.
The Core Product, MT1013, is a self-developed dual-targeting receptor agonist polypeptide that simultaneously targets the CaSR and the OGP receptor. It is primarily designed for the treatment of Chronic Kidney Disease-Secondary Hyperparathyroidism (CKD-SHPT), with potential for expansion into additional indications such as CKD-MBD with osteoporosis and non-dialysis CKD-SHPT. In previously completed clinical studies, MT1013 has demonstrated multiple clinical advantages, including significant improvement in comprehensive control rate, fast-acting and sustained efficacy, potential cardiovascular benefits, a favorable safety and tolerability profile, as well as enhanced bone mineral density and metabolism. Besides, Micot also has three Key Products: XTL6001 (a GLP-1R/GCGR/MasR triple-target agonist for chronic weight management in obese or overweight populations, proteinuric CKD, and MASH); MT1002 (a coagulation factor II and GPIIb/IIIa dual-targeting peptide antagonist for ACS-PCI, stroke, HD anticoagulation, HD-PF4, and other indications); and MT200605 (a neuroprotectant for injection that blocks the post-ischemic pathological cascade via a dual synergistic mechanism).
About CMSI
China Merchants Securities International Company Limited ("CMSI"), a wholly-owned subsidiary of China Merchants Securities Co., Ltd ("China Merchants Securities", Stock Code: 600999.SH/6099.HK), founded in Hong Kong, is the main overseas business platform of China Merchants Securities, and the vital bridge between China Merchants Securities and the international capital markets. China Merchants Securities (HK) Co., Limited is a licensed subsidiary of CMSI in Hong Kong and acted as a sponsor of this IPO.
CMSI has established subsidiaries in Hong Kong and Seoul; providing clients with a one-stop full range of integrated financial services, including stocks and futures brokerage, corporate finance, sales and trading, asset management, private equity and OTC derivatives , etc.
Leveraging Hong Kong while engaging the world, relying on the century-old brand of "China Merchants", the strong industrial network coverage and the resource advantages accumulated in mainland China and overseas, CMSI strives to become an international modern securities brokerage firm with a full range of financial service capabilities through creating values with excellent services.